UPDATE: TetraLogic Reports Temporary Halt of Chronic Hep B Trial

TetraLogic Pharmaceuticals Corporation TLOG, a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced that it has temporarily halted enrollment in the birinapant chronic hepatitis B multiple ascending dose trial, currently being conducted in Australia, due to cranial nerve palsies observed in the first cohort.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDAPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!